Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 5 de 5
Filtrer
1.
Biol. Res ; 51: 39, 2018. graf
Article de Anglais | LILACS | ID: biblio-983941

RÉSUMÉ

BACKGROUND: SET domain bifurcated 1 (SETDB1) has been widely considered as an oncogene playing a critical role in many human cancers, including breast cancer. Nevertheless, the molecular mechanism by which SETDB1 regulates breast cancer tumorigenesis is still unknown. METHODS: qRT-PCR assay or western blot analysis was performed to assess the expression level of SETDB1 mRNA or protein, respectively. siSETDB1, pCMV6-XL5-SETDB1, miR-381-3p mimic, or miR-381-3p inhibitor was transfected into cells to regulate the expression of SETDB1 or miR-381-3p. MiRNA directly interacted with SETDB1 was verified by luciferase reporter assay and RNA immunoprecipitation. CCK-8 assay, colony formation assay, flow cytometric analysis, and transwell assay were used to detect the abilities of cell proliferation, cell cycle progression and migration, respectively. Animal model of xenograft tumor was used to observe the regulatory effect of SETDB1 on tumor growth in vivo. RESULTS: We verified that SETDB1 mRNA level was upregulated in breast cancer tissues and cell lines, and SETDB1 depletion led to a suppression of cell proliferation, cell cycle progression and migration in vitro, as well as tumor growth in vivo. SETDB1 was verified to be a target of miR-381-3p. Moreover, miR-381-3p overexpression suppressed cell proliferation, cell cycle progression and migration, whereas SETDB1 abated miR-381-3p-mediated regulatory function on breast cancer cells. CONCLUSIONS: This study revealed that SETDB1 knockdown might suppress breast cancer progression at least partly by miR-381-3p-related regulation, providing a novel prospect in breast cancer therapy.


Sujet(s)
Humains , Animaux , Mâle , Femelle , Souris , Protein Methyltransferases/génétique , Tumeurs du sein/génétique , microARN/métabolisme , Protein Methyltransferases/métabolisme , Cellules souches , Tumeurs du sein/anatomopathologie , Histone-lysine N-methyltransferase , RT-PCR , microARN/génétique , Lignée cellulaire tumorale , Prolifération cellulaire , Modèles animaux de maladie humaine , Techniques de knock-down de gènes , Cytométrie en flux , Souris de lignée BALB C
2.
Article de Anglais | WPRIM | ID: wpr-131297

RÉSUMÉ

Protein arginine methylation is important for a variety of cellular processes including transcriptional regulation, mRNA splicing, DNA repair, nuclear/cytoplasmic shuttling and various signal transduction pathways. However, the role of arginine methylation in protein biosynthesis and the extracellular signals that control arginine methylation are not fully understood. Basic fibroblast growth factor (bFGF) has been identified as a potent stimulator of myofibroblast dedifferentiation into fibroblasts. We demonstrated that symmetric arginine dimethylation of eukaryotic elongation factor 2 (eEF2) is induced by bFGF without the change in the expression level of eEF2 in mouse embryo fibroblast NIH3T3 cells. The eEF2 methylation is preceded by ras-raf-mitogen-activated protein kinase kinase (MEK)-extracellular signal-regulated kinase (ERK1/2)-p21(Cip/WAF1) activation, and suppressed by the mitogen-activated protein kinase (MAPK) inhibitor PD98059 and p21(Cip/WAF1) short interfering RNA (siRNA). We determined that protein arginine methyltransferase 7 (PRMT7) is responsible for the methylation, and that PRMT5 acts as a coordinator. Collectively, we demonstrated that eEF2, a key factor involved in protein translational elongation is symmetrically arginine-methylated in a reversible manner, being regulated by bFGF through MAPK signaling pathway.


Sujet(s)
Animaux , Souris , Arginine , Dédifférenciation cellulaire , Inhibiteur p21 de kinase cycline-dépendante/génétique , Elongation Factor 2 Kinase/métabolisme , Facteur de croissance fibroblastique de type 2/métabolisme , Fibroblastes/métabolisme , Flavonoïdes/pharmacologie , Système de signalisation des MAP kinases/effets des médicaments et des substances chimiques , Méthylation , Mitogen-Activated Protein Kinases/antagonistes et inhibiteurs , Myofibroblastes/anatomopathologie , Cellules NIH 3T3 , Protein Methyltransferases/métabolisme , Protein-arginine N-methyltransferases/métabolisme , Petit ARN interférent/génétique
3.
Article de Anglais | WPRIM | ID: wpr-131300

RÉSUMÉ

Protein arginine methylation is important for a variety of cellular processes including transcriptional regulation, mRNA splicing, DNA repair, nuclear/cytoplasmic shuttling and various signal transduction pathways. However, the role of arginine methylation in protein biosynthesis and the extracellular signals that control arginine methylation are not fully understood. Basic fibroblast growth factor (bFGF) has been identified as a potent stimulator of myofibroblast dedifferentiation into fibroblasts. We demonstrated that symmetric arginine dimethylation of eukaryotic elongation factor 2 (eEF2) is induced by bFGF without the change in the expression level of eEF2 in mouse embryo fibroblast NIH3T3 cells. The eEF2 methylation is preceded by ras-raf-mitogen-activated protein kinase kinase (MEK)-extracellular signal-regulated kinase (ERK1/2)-p21(Cip/WAF1) activation, and suppressed by the mitogen-activated protein kinase (MAPK) inhibitor PD98059 and p21(Cip/WAF1) short interfering RNA (siRNA). We determined that protein arginine methyltransferase 7 (PRMT7) is responsible for the methylation, and that PRMT5 acts as a coordinator. Collectively, we demonstrated that eEF2, a key factor involved in protein translational elongation is symmetrically arginine-methylated in a reversible manner, being regulated by bFGF through MAPK signaling pathway.


Sujet(s)
Animaux , Souris , Arginine , Dédifférenciation cellulaire , Inhibiteur p21 de kinase cycline-dépendante/génétique , Elongation Factor 2 Kinase/métabolisme , Facteur de croissance fibroblastique de type 2/métabolisme , Fibroblastes/métabolisme , Flavonoïdes/pharmacologie , Système de signalisation des MAP kinases/effets des médicaments et des substances chimiques , Méthylation , Mitogen-Activated Protein Kinases/antagonistes et inhibiteurs , Myofibroblastes/anatomopathologie , Cellules NIH 3T3 , Protein Methyltransferases/métabolisme , Protein-arginine N-methyltransferases/métabolisme , Petit ARN interférent/génétique
4.
Article de Anglais | WPRIM | ID: wpr-56321

RÉSUMÉ

C-Terminal carboxyl methylation of a human placental 23 kDa protein catalyzed by membrane-associated methyltransferase has been investigated. The 23 kDa protein substrate methylated was partially purified by DEAE-Sephacel, hydroxyapatite and Sephadex G-100 gel filtration chromatographies. The substrate protein was eluted on Sephadex G-100 gel filtration chromatography as a protein of about 29 kDa. In the absence of Mg2+, the methylation was stimulated by guanine nucleotides (GTP, GDP and GTPgammaS), but in the presence of Mg2+, only GTPgammaS stimulated the methylation which was similar to the effect on the G25K/rhoGDI complex. AFC, an inhibitor of C-terminal carboxyl methylation, inhibited the methylation of human placental 23 kDa protein. These results suggests that the substrate is a small G protein different from the G25K and is methylated on C-terminal isoprenylated cysteine residue. This was also confirmed by vapor phase analysis. The methylated substrate protein was redistributed to membrane after in vitro methylation, suggesting that the methylation of this protein is important for the redistribution of the 23 kDa small G protein for its putative role in intracellular signaling.


Sujet(s)
Femelle , Humains , Grossesse , Cystéine/métabolisme , Protéines G/métabolisme , Nucléotides guanyliques/pharmacologie , Méthylation , Placenta/métabolisme , Placenta/enzymologie , Protéines de la grossesse/métabolisme , Protein Methyltransferases/métabolisme
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE